Replies to post #394046 on NorthWest Biotherapeutics Inc (NWBO)

[jondoeuk]

Oh, he's popped up a few times over the years, always being critical of autologous DC vaccines.

No, not just DC based vaccines.

He runs a lab working on a different approach, namely adoptive cell transfer (ACT) targeting specific tumor mutations.

He also collaborated with Dr. Eshhar in the 90s and was one of the first to test an anti-CD19 CAR-T (Kite Pharma took that forward).

Also, TCRs targeting TAAs, such as NY-ESO-1 (GSK is running a pivotal trial in STS using ADAP's TCR targeting that) https://clincancerres.aacrjournals.org/content/21/5/1019.long

And most researchers like to think that their investigational therapy is the one with the magic bullet, so are prone to making negative comparisons about others.

As I've said, the clinical data from trials testing vaccines has and continues to remain very poor.